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Figure S1.  Proposed mechanism for the addition of CO2 to epoxides.
[1] 
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Figure S2. Molecular structures showing the modifications of the azaphosphatrane 
environment in the encapsulated azaphosphatranes 1a and 1b and in the opened face model 
2a.
[2,3]
 
 
 
 
 
Figure S3. View of the molecular structure of 1b above the PH moiety, showing the limited 
accessibility to the phosphorus site (The CTV cap has been omitted for clarity).
[3]
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General information 
Commercial reagents were used without further purifications. NMR spectra of compounds 
(
1
H, 
13
C, 
31
P) were performed on a Bruker spectrometer at 500.1, 125.7 and 202.4 MHz 
respectively. Yields were estimated during catalytic runs by 
1
H NMR with a Bruker Avance 
300 spectrometer at 300.1 MHz. Mass spectra were performed by the Service Central 
d'Analyses, CNRS, France. CO2 of a purity of 99.99 % is commercially available and used 
without further purification. 
 
 
Synthetic strategies for azaphosphatrane derivatives  
 
 
Scheme S1. Synthesis strategy for open-faced azaphosphatrane derivatives.
[2]
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A modular synthesis of hemicryptophanes has been developed which allowed us to have 
access to several molecular containers with different shapes and sizes of the cavities.
[4]
 The 
phosphorus was then inserted according to the procedure described previously for 1a-b and 
1d and for the model compounds 2a-b and 2d.
[2,3]
 
 
 
 
Scheme S2. Synthesis strategy for encaged azaphosphatrane derivatives. 
  
Syntheses of new compounds 
Synthesis of tris((4-methoxynaphthalen-1-yl)methyl)tren  
In a round bottom flask, tris(2-aminoethyl)amine (tren) (412 mg, 
2.82 mmol) was dissolved in methanol (10 mL) and ice-bath 
cooled. Then, a solution of aldehyde (2.10 g, 11.3 mmol, 4.0 eq) in a 1:1 (v/v) mixture of 
chloroform/methanol (10 mL) was added drop-wise. The reaction was slowly warmed to 
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room temperature and stirred overnight. Methanol (10 mL) was then added. Subsequent 
portions of NaBH4 (878 mg, 23.2 mmol) were added over a thirty-minute period. Solvents 
were evaporated. A solution of 10% NaOH in water was added (25 mL), and the resulting 
mixture was extracted with toluene (3 x 30 mL). The combined organic phases were extracted 
with HCl 1M (3 x 50mL) and the combined aqueous phases were then basified with an 
aqueous 10% NaOH solution. The solution was then extracted with toluene (3 x 100 mL) and 
the organic layers were dried over Na2SO4, filtered, and the solvent was removed under 
reduced pressure to give a pale yellow solid (1.44 g, 78 %).  
1
H NMR (CDCl3, 298 K, 500.1 MHz): δ 8.32-8.30 (m, 3H); 7.96-7.94 (m, 3H); 7.48-7.46 (m, 
6H); 7.26 (d, 
3
J = 7.80 Hz, 3H, ArH); 6.55 (d,
3
J = 7.80 Hz, 3H, ArH); 4.07 (s, 6H ArCH2N); 
3.93 (s, 9H, ArOCH3); 2.76 (t, 
3
J = 5.97 Hz, 6H, NCH2CH2N); 2.65 (t, 
3
J = 5.97 Hz, 6H, 
NCH2CH2N). 
13
C NMR (CDCl3, 298 K, 125.7 MHz): δ 154.9 (CAr); 132.6 (CAr); 127.5 (CAr); 
126.6 (CArH); 126.1 (CArH); 125.9 (CAr); 125.0 (CArH); 123.4 (CArH); 122.6 (CArH); 103.1 
(CArH); 55.4 (OCH3); 54.4 (ArCH2N); 51.0 (NCH2CH2N); 47.5 (NCH2CH2N). ESI-HRMS 
m/z calcd for C42H49N4O3 [M+H]
+
 657.3799, found 657.3776. Mp = 122°C. 
 
Synthesis of tris((4-methoxynaphthalen-1-yl)methyl) 
azaphosphatrane (2c) 
In an ice-bath cooled round bottom flask, 
tris(dimethylamino)phosphine (0.273 mL, 1.50 mmol) was 
dissolved in acetonitrile (15 mL). Phosphorus trichloride (65 µL, 0.75 mmol) was then added 
drop-wise. The reaction mixture was vigorously stirred at 0 °C for 0.5 h, and a solution of the 
tris((4-methoxynaphthalen-1-yl)methyl)tren ligand (1.338 g, 2.04 mmol) in acetonitrile (10 
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mL) was added drop-wise. The reaction mixture was then stirred overnight at room 
temperature. The solvent was removed under reduced pressure and the crude compound was 
chromatographed on silica gel eluting with CHCl3/MeOH 15/1 to give pure 2c as an off-white 
powder (663 mg, 45 % yield). 
1
H NMR (CDCl3, 298 K, 500.1 MHz): δ 8.34 (d, 
3
J = 8.10 Hz, 3H, ArH); 7.75 (d,
 3
J = 8.12 
Hz, 3H, ArH); 7.52-7.45 (m, 6H); 7.18 (d, 
3
J = 7.81 Hz, 3H, ArH); 6.71 (d,
3
J = 7.81 Hz, 3H, 
ArH); 6.04 (d, 
1
JP-H = 494 Hz, 1H, PH); 4.42 (d, 
3
JP-H = 14.47 Hz, 6H ArCH2N); 4.00 (s, 9H, 
ArOCH3); 3.71-3.68 (m, 6H, NCH2CH2N); 3.19-3.15 (m, 6H, NCH2CH2N). 
13
C NMR 
(CDCl3, 298 K, 125.7 MHz): δ 155.4 (CAr); 131.9 (CAr); 126.8 (CArH); 126.0 (CAr); 125.8 
(CArH); 125.3 (CArH); 124.0 (CAr); 123.0 (CArH); 122.4 (CArH); 103.2 (CArH); 55.6 (OCH3); 
49.0 (ArCH2N); 47.5 (NCH2CH2N); 39.9 (NCH2CH2N).  
31
P NMR (298 K, CDCl3, 202.4 
MHz): δ -16.8 (d, 1JP-H = 494 Hz). IR (KBr) = 1584; 1461; 1391; 1272; 1113; 1087 cm
-1
. Mp= 
320°C. ESI-HRMS m/z calcd for C42H46N4O3P [M]
+
 685.3302, found 685.3271. 
 
 Synthesis of hemicryptophane-azaphosphatrane (1c) 
In an ice-bath cooled round bottom flask, 
tris(dimethylamino)phosphine (0.151 mL, 0.83 mmol) was 
dissolved acetonitrile (14 mL) and phosphorous trichloride 
(0.040 mL, 0.47 mmol) was then added drop-wise. The reaction 
mixture was vigorously stirred at 0°C for 0.5 h, and a solution of 
the 4-methoxynaphthalen hemicryptophane ligand
[3]
 (898 mg, 0.816 mmol) in acetonitrile (7 
mL) was added dropwise. The mixture was then heated to 40°C for 2 days. The solvent was 
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then removed under vacuum and the residue was purified by column chromatography eluting 
with CH2Cl2/MeOH (15/2) to give pure 1c
 
(226 mg, 24% yield) as a light brown solid.  
1
H NMR (C2D2Cl4, 362 K, 501.1 MHz): δ 7.54 (broad, 3H); 7.15 (broad, 3H); 6.92 (s, 3H, 
ArH); 6.80 (broad, 6H); 6.68 (s, 3H, ArH); 6.48 (broad, 3H); 6.24 (d, J = 7.78 Hz); 5.41 (d, 
1
JP-H  = 509 Hz, 1H, P-H); 4.74 (d, 
2
J = 13.7 Hz, 3H); 4.44-4.41 (m, 3H, OCH2CH2); 4.30-
4.23 (m, 9H, OCH2CH2); 4.03 (t, J = 15.97 Hz, 3H); 3.90 (t, J = 15.97 Hz, 3H); 3.53-3.49 (m, 
9H); 3.25 (s, 9H, OCH3); 3.25-3.16 (m, 6H).  
13
C NMR (CDCl3, 298 K, 125.7 MHz): δ 154.2; 
149.5; 146.6; 134.2; 132.5; 131.8; 126.9; 126.0; 125.1; 123.6; 122.8; 122.3; 119.4; 116.5; 
114.8; 103.5; 68.6; 67.2; 56.0; 50.3; 47.8; 36.7.  
31
P NMR (298 K, CDCl3, 202.4 MHz): δ -
28.5 (d, 
1
JP-H = 509 Hz). IR (KBr) = 1582; 1507; 1460; 1394; 1264; 1086; 722 cm
-1
. ESI-
HRMS m/z calcd for C69H70N4O9P [M]
+
 1129.4875, found 1129.4833.  
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NMR data 
 
Figure S4. 
1
H RMN (CDCl3, 500.1 MHz) of tris((4-methoxynaphthalen-1-yl)methyl)tren. 
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Figure S5. 
1
H NMR (CDCl3, 500.1 MHz) of tris((4-methoxynaphthalen-1-yl)methyl) 
azaphosphatrane (2c). 
S10 
 
 
Figure S6. 
31
P NMR (CDCl3, 202.4 MHz) of tris((4-methoxynaphthalen-1-yl)methyl) 
azaphosphatrane (2c). 
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Figure S7. 
1
H NMR (CD2Cl4, 500.1 MHz, 362 K) of hemicryptophane-azaphosphatrane (1c). 
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Figure S8. 
31
P NMR (CDCl3, 202.4 MHz) of hemicryptophane-azaphosphatrane (1c). 
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Catalytic procedures 
 Reactions were carried out in a 5 mL Schlenk tube equipped with a rubber septum. In a 
typical run, the reactor was charged with the required quantity of styrene oxide (5 or 50 
mmol), 0.05 mmol of catalyst (1a-d or 2a-d) and 2,4-dibromo-mesitylene (yields were 
estimated from the 
1
H NMR spectra using 2,4-dibromo-mesitylene as an internal standard). 
Carbon dioxide was first bubbled into the solution for five minutes to saturate the liquid 
phase. A balloon filled with carbon dioxide was then connected to the Schlenk through a 
needle to maintain a constant atmosphere of carbon dioxide during the course of the reaction. 
The mixture was placed in a thermostatic oil bath at the required temperature and stirred at a 
stirring speed of 1000 rounds min
-1
. In the case of the kinetic studies conducted over 4 days, 
the reaction mixture was cooled to room temperature after each 24 hour period and an aliquot 
was analyzed by 
1
H NMR. Based on the styrene oxide integrated intensity in the NMR 
spectrum, additional substrate was added to the mixture to recover the initial substrate to 
catalyst ratio. Carbon dioxide was bubbled through the solution for fifteen minutes at room 
temperature, the CO2 reservoir was connected to the reaction vessel, which was returned to 
the thermostatic bath. 
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